GTBL paid ¥21.5 billion (Rs 1,300 crore) for MicroBiopharm via its Japanese subsidiary.
The purchase was financed with a Rs 475 crore capital injection and a Rs 800 crore loan, arranged by Avendus Capital.
MicroBiopharm operates three GMP‑compliant plants, earned ¥9.5 billion in FY26, and supplies 40 % of its revenue outside Japan.
The acquisition adds a proprietary P450 enzyme platform, plasmid DNA, ADC conjugation and recombinant protein capabilities to GTBL’s fermentation base.
GTBL expects the transaction to be earnings‑per‑share accretive and to improve cost competitiveness on higher‑value products.
💡 Why It Matters
The deal marks a significant expansion for GTBL, a company that has traditionally focused on fermentation‑based drug manufacturing. By acquiring a well‑established Japanese player with GMP facilities and a diversified technology stack, GTBL can offer a wider range of services to international pharmaceutical firms. This positions the company to compete more effectively in the growing CDMO sector, potentially boosting its revenue streams and profitability.
Acquisition Completed Gujarat Themis Biosyn Limited (GTBL) announced on Friday that it has finished its purchase of Japan‑based MicroBiopharm Japan Co., Ltd. (MBJ). The transaction, first disclosed on 22 May, was finalised through GTBL’s wholly‑owned Japanese arm, Themis Biosyn Japan Limited (TBJ), after all regulatory approvals and closing conditions were met.
Financial Details GTBL paid a total of ¥21.5 billion, equivalent to roughly Rs 1,300 crore, for MBJ. To fund the deal, the company injected Rs 475 crore as a capital contribution into TBJ and secured a loan of up to Rs 800 crore, also through TBJ. Avendus Capital structured the entire financing package, combining onshore and offshore debt, with Avendus Structured Credit Fund III leading the onshore tranche.
Strategic Implications The acquisition expands GTBL’s reach beyond its core fermentation activities. MBJ brings three GMP‑certified manufacturing sites, a proprietary P450 enzyme platform for bioconversion, and expertise in plasmid DNA, antibody‑drug conjugate (ADC) conjugation and recombinant proteins. Its product portfolio includes active pharmaceutical ingredients (APIs) and intermediates for oncology, immunosuppressants, peptides and antibiotics.
MBJ’s revenue stood at ¥9.5 billion in FY26, with about 40 % sourced from markets outside Japan. Six of its largest customers have maintained relationships with the company for more than two decades, underscoring its established global footprint. By merging GTBL’s low‑cost Indian manufacturing base with MBJ’s technology and customer network, the company aims to enhance cost competitiveness and potentially lift margins on higher‑value offerings.
Dr. Sachin Patel, managing director of GTBL, described the deal as a “defining milestone” in the firm’s evolution toward a globally integrated contract development and manufacturing organisation (CDMO). MBJ’s management will continue to run the Japanese operations post‑acquisition.
Future Outlook With the new capabilities, GTBL is positioned to broaden its service portfolio and deepen its presence in the CDMO market. The company anticipates that the transaction will be earnings‑per‑share accretive, signalling a positive impact on shareholder value. Stakeholders will likely monitor how GTBL integrates MBJ’s technology platforms and how the combined entity scales its global client base in the coming quarters.
🏛️ Background & Context
GTBL has been pursuing a strategy to transition from a niche fermentation manufacturer to a full‑service CDMO. The acquisition of MBJ, with its long history of R&D and manufacturing expertise, aligns with this vision and provides immediate access to advanced bioconversion technologies and a global customer base.
👁️ What To Watch Next
Investors and industry observers should keep an eye on how GTBL integrates MBJ’s operations, the performance of the newly added enzyme and ADC platforms, and any subsequent expansion of its CDMO service offerings. The company’s earnings reports will also reveal whether the transaction delivers the projected accretive effect on earnings per share.
Source Attribution:
Gujarat Themis Biosyn Limited completes acquisition of MicroBiopharm Japan Co., Ltd.
